Minimal, measurable, atypical

ESH eLearning, Nick CROSS, 257024

Identification of metabolic vulnerabilities in leukemic stem cells using the integrative omic approach 

ESH eLearning, Zuzana Brabcova, 257023

TNFα-induced bone marrow stromal niche alterations enhance leukemic stem cell growth via CXCL1/CXCR2 signaling

ESH eLearning, Puneet Agarwal, 257022

Spirit 2: final analysis of an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML

ESH eLearning, Stephen OBrien, 257021

Why the fuss over CML stem cells ?

ESH eLearning, Robert Peter GALE, 234565

Mastocytosis

ESH eLearning, Jason Gotlib, 219417

Are we using personalized treatment for patients with myelofibrosis?

ESH eLearning, Alessandro Vannucchi, 219254

Stem cell depletion therapy is needed to change the natural history of the MPNs

ESH eLearning, Ronald Hoffman, 219253

Dissecting the molecular genetics of MPN

ESH eLearning, Ann Mullally, 219252

Epigenetics in myeloproliferative neoplasms

ESH eLearning, Mary Frances McMullin, 219251

Megakaryocyte differentiation therapy in the MPNs

ESH eLearning, John D. Crispino, 219250

Role of epigenetic dysregulation in MPN pathogenesis

ESH eLearning, Ross Levine, 219249

MPN Drivers: from active JAK2 and TpoR mutants to rogue calreticulin and their role in progression

ESH eLearning, Stefan Constantinescu, 219248

Somatic mutations and clonal relationships

ESH eLearning, Peter Campbell, 219247

CAR T-cells

ESH eLearning, Noëlle Frey, 219268

Antibodies & antibody conjugates

ESH eLearning, Wendy Stock, 219267

Tumor target antigens in AML

ESH eLearning, Marion Subklewe, 219266

Low-intensity treatments

ESH eLearning, Hervé Dombret, 219265

Maintenance therapy after transplantation

ESH eLearning, Charles Craddock, 219264

Gemtuzumab Ozogamicin

ESH eLearning, Alan Burnett, 219263

Therapy of acute promyelocytic leukemia

ESH eLearning, Lionel ADES, 219262

IDH inhibitors

ESH eLearning, Eytan Stein, 219261

FLT3 inhibitors

ESH eLearning, Mark J Levis, 219260

Salvage therapy

ESH eLearning, Arnold Ganser, 219259

Treatment of poor ELN risk AML

ESH eLearning, Richard Schlenk, 219258

The devastating effects of relapsed or refractory AML

ESH eLearning, Arnold Ganser, 226250

Understanding gene-gene interactions via machine learning: Pandora’s box?

ESH eLearning, Andrew Wei, 226246

The complications of treating elderly patients with AML

ESH eLearning, Gail Roboz, 226272

The latest clinical trials into novel AML therapies

ESH eLearning, Eytan Stein, 226271

Encouraging patients to participate in AML trials

ESH eLearning, Eytan Stein, 226270

Primary and secondary resistance in AML

ESH eLearning, Eytan Stein, 226269

Support systems are a crucial factor in ALL treatment

ESH eLearning, Wendy Stock, 226286

Emerging novel approaches for ALL: inotuzumab ozogamicin

ESH eLearning, Wendy Stock, 226285

Next-generation methodologies: the future for MRD monitoring in ALL?

ESH eLearning, Wendy Stock, 226284

The importance of MRD assessment in all phases of ALL treatment

ESH eLearning, Noelle Frey, 226283

The CAR T-cell therapy race

ESH eLearning, Noelle Frey, 226282

CAR T-cell therapy and ALL: the current landscape

ESH eLearning, Noelle Frey, 226281

Involving the patient is a key part of cancer treatment

ESH eLearning, Mark Levis, 226280

Immunotherapy clinical trial participation in R/R AML

ESH eLearning, Marion Subklewe, 226279

Diagnosis of ph-like ALL

ESH eLearning, Charles Mullighan, 219255

Leukemic stem cells modulate the bone marrow microenvironment

ESH eLearning, Dominique Bonnet, 219256

Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No

ESH eLearning, Farhad Ravandi, 219257

Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

ESH eLearning, Eytan Stein, 226268

Targeting IDH mutations for the treatment of AML

ESH eLearning, Eytan Stein, 226267

Biological rationales when determining AML therapies

ESH eLearning, Christoph Röllig, 226266

Managing AML in elderly patients

ESH eLearning, Christoph Röllig, 226265

Immunotherapies for the treatment of AML

ESH eLearning, Christoph Röllig, 226264

MRD detection techniques in AML: pros and cons

ESH eLearning, Christoph Röllig, 226263

Applying the right therapies to the right AML patient population

ESH eLearning, Christoph Röllig, 226262

Combination therapy for the treatment of AML

ESH eLearning, Christoph Röllig, 226261

How can we improve CAR T-cell therapy?

ESH eLearning, Marion Subklewe, 226278

Exciting immunotherapy clinical trials for the management of AML

ESH eLearning, Marion Subklewe, 226277

The challenges of choosing the right target antigen in AML compared to ALL

ESH eLearning, Marion Subklewe, 226276

Increasing AML clinical trial participation rates

ESH eLearning, Gail Roboz, 226275

Managing relapse in AML: the role of MRD

ESH eLearning, Gail Roboz, 226273

Improving the activity of BH3 mimetic venetoclax: a case study

ESH eLearning, Andrew Wei, 226247

Clinical trials investigating venetoclax combinations for AML

ESH eLearning, Andrew Wei, 226248

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias

ESH eLearning, Arnold Ganser, 226249

Combining existing drugs for the creation of novel AML therapies

ESH eLearning, Gail Roboz, 226274

From bench to the bedside: understanding the genetic changes in AML

ESH eLearning, Arnold Ganser, 226251

Finding the right targets for CAR T-cell therapy in AML

ESH eLearning, Arnold Ganser, 226252

Midostaurin: the first drug to receive approval for AML since 2000

ESH eLearning, Arnold Ganser, 226253

Overcoming the issues with clinical trial recruitment

ESH eLearning, Arnold Ganser, 226254

Transplantation clinical trial network to build available prospective studies on AML

ESH eLearning, Charles Craddock, 226255

Current understandings of ALL approaches

ESH eLearning, Charles Craddock, 226256

Challenges with the identification of ALL subtypes

ESH eLearning, Charles Craddock, 226257

Improving response to ALL therapies

ESH eLearning, Charles Craddock, 226258

Minimal residual disease: a key determinant of ALL treatment response

ESH eLearning, Charles Craddock, 226259

Increasing the effectiveness of ALL therapies

ESH eLearning, Charles Craddock, 226260

Bone marrow transplant in red cell disorders

ESH eLearning, Eliane Gluckman, 219043

Sickle cell disease pathophysiology

ESH eLearning, Jacques Elion, 219038

Red cell senescence and storage lesions

ESH eLearning, Giel Bosman, 219042

Epidemiology of red cell disorders

ESH eLearning, Fred Piel, 219041

Malaria and red cell disorders

ESH eLearning, Michael Lanzer, 219040

Thalassaemias

ESH eLearning, Maria Domenica Cappellini, 219039

Erythroid niche and erythroblast maturation

ESH eLearning, Mohandas Narla, 219034

Epigenetics in erythropoiesis

ESH eLearning, Gordon D. Ginder, 219035

Heme synthesis and iron metabolism

ESH eLearning, Laurent Gouya, 219036

Red cells and oxidative stress

ESH eLearning, Lucia De Franceschi, 219037

Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies

ESH eLearning, Davide Rossi, 212197

Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy

ESH eLearning, Christian REINHARDT, 212198

Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient

ESH eLearning, Paul Hamlin, 212199

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

ESH eLearning, Loretta Nastoupil, 212196

Biology of AML at older age

ESH eLearning, Terrence N. Wong, 212185

Therapeutic management of the so-called “fit” older patient with AML

ESH eLearning, Bob Löwenberg, 212186

Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies

ESH eLearning, Farrukh Awan, 212195

Management of the unfit patient with AML

ESH eLearning, Gert Ossenkoppele, 212187

The older patient with ALL

ESH eLearning, Hervé Dombret, 212188

Alloegeneic stem cell transplantation at older age

ESH eLearning, Nicolaus Kröger, 212189

Clonal evolution of multiple myeloma

ESH eLearning, Nikhil Munshi, 212190

MGUS and MGUS transition to myeloma, what do we need to do?

ESH eLearning, Irene Ghobrial, 212191

Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.

ESH eLearning, Jesús San Miguel, 212192

Clonal evolution in malignant lymphoma

ESH eLearning, Jude FITZGIBBON, 212193

Management of indolent lymphoma in the elderly patient

ESH eLearning, Loretta Nastoupil, 212194

Anemia at older age

ESH eLearning, Nancy Berliner, 212179

Aging stem cells and stress

ESH eLearning, Michael Milsom, 212178

Selection of TP53 mutant clones following chemotherapy

ESH eLearning, Terrence N. Wong, 212177

Clonal hematopoiesis

ESH eLearning, George Vassiliou, 212176

Clonal hematopoiesis

ESH eLearning, Benjamin Ebert, 212175

DNA damage, a driving force of aging

ESH eLearning, Björn Schumacher, 212174